文献速递神经肿瘤

次全切除术后放疗在复发WHO 1级且具中/高危分子特征的脑膜瘤中的应用

Postoperative radiotherapy in subtotally resected recurrent WHO grade 1 meningiomas with intermediate-/high-risk molecular profiles.
PubMed 文献 · Neuro Oncol · 2025-01-01

该回顾性研究纳入210例具DNA甲基化谱的CNS WHO 1级脑膜瘤患者,按整合评分分为低、中/高危。新诊断病例中,全切除3年无进展生存率为93.0%,次全切除为69.3%;中/高危组全切除后为85.9%,次全切除后为40.0%。复发后次全切除加术后放疗3年无进展生存率可达88.9%。

要点

  • 新诊断WHO 1级脑膜瘤全切除3年无进展生存率93.0%,次全切除69.3%。
  • 整合评分中/高危组全切除后3年无进展生存率85.9%,次全切除后40.0%。
  • 复发后次全切除加术后放疗3年无进展生存率88.9%。

核心结论

  • 新诊断病例的预后受切除程度和分子风险谱共同影响;低风险原发病例可保守管理,复发或高危患者可能从早期术后放疗中获益。

研究设计与样本

  • 回顾性研究纳入210例CNS WHO 1级脑膜瘤且具备DNA甲基化谱的患者,评估肿瘤特征和治疗过程,以局部无进展生存为主要终点,采用Kaplan-Meier和Cox回归分析。

主要发现

  • 新诊断病例中,全切除3年无进展生存率93.0%,次全切除69.3%。
  • 整合评分低危组全切除后3年无进展生存率93.4%,次全切除后77.4%。
  • 整合评分中/高危组全切除后3年无进展生存率85.9%,次全切除后40.0%。
  • 复发后次全切除加术后放疗3年无进展生存率88.9%,新诊断次全切除未行辅助放疗者3年无进展生存率40.0%。

关键数值与推荐

  • 整合评分基于甲基化家族(DKFZ脑肿瘤分类器)、CNS WHO分级和染色体缺失计算,分为低、中、高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Meningiomas represent the most common primary intracranial tumors in adults, with World Health Organization (WHO) grade 1 typically associated with favorable outcomes following gross total resection (GTR). METHODS: This retrospective study included patients with CNS WHO grade 1 meningioma and available DNA methylation profiles (n = 210). Clinical tumor characteristics and treatment course (eg, surgical resection, extent of resection, radiotherapy [RT]) were evaluated. Integrated Scores (InS) were calculated based on methylation family using the DKFZ brain tumor classifier, CNS WHO grading, and chromosomal losses, categorized as low, intermediate, or high. Survival analyses employed Kaplan-Meier and Cox regression methods, with local PFS defined as the primary endpoint. RESULTS: In newly diagnosed cases, GTR was associated with a 93.0% 3-year progression-free survival (PFS), compared to 69.3% following subtotal resection (STR). Stratification by IntS showed that patients in the IntS-low group had superior outcomes: 3-year PFS of 93.4 after GTR and 77.4% after STR. In contrast, patients with IntS-intermediate/high profiles showed significantly worse outcomes, with PFS of 85.9% after GTR and 40.0% after STR. Following tumor recurrence, particularly those with IntS-intermediate/high, postoperative RT after STR may improve 3-year PFS to 88.9%, compared to much lower PFS rates in newly diagnosed cases managed without adjuvant RT after STR (3-year PFS: 40.0%). CONCLUSIONS: Our findings highlight the combined impact of both the extent of resection and molecular risk profile on prognosis in newly diagnosed cases. While conservative management is feasible in lower-risk primary cases, recurrent or higher-risk patients may benefit from early postoperative RT.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Deng MY, Maas SLN, Anil G, et al. Postoperative radiotherapy in subtotally resected recurrent WHO grade 1 meningiomas with intermediate-/high-risk molecular profiles. Neuro Oncol. 2025. PMID: 40424588. doi:10.1093/neuonc/noaf125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。